Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgerySierra Health and Life Uplizna Coverage Update | O…
    Ask Trek AI about this page
    Modifiedsierra health and lifePolicy 2026D0091J

    Uplizna (inebilizumab-cdon) — Clinical Coverage Criteria

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0091J alerts

    Get alerted when Policy 2026D0091J changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical policy governing clinical coverage criteria, prior authorization, and continuation requirements for Uplizna (inebilizumab-cdon) as treatment for neuromyelitis optica spectrum disorder (NMOSD), immunoglobulin G4-related disease (IgG4-RD), and generalized myasthenia gravis (gMG) for Sierra Health and Life members.

    Policy Summary
    Payersierra health and life
    PolicyUplizna (inebilizumab-cdon) — Clinical Coverage Criteria
    Policy CodePolicy 2026D0091J
    Change TypeModified coverage criteriaadded gMG indicationsremoved NMOSD relapse-count requirement
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with documented diagnosis, serology, MGFA class II–IV and MG-ADL ≥5 (for gMG) and required supporting medical records per policy.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Revised coverage criteria for Neuromyelitis Optica Spectrum Disorder (NMOSD) removing prior relapse-count requirements.

    Added language indicating Uplizna is proven and medically necessary for treatment of gMG in patients who are anti-AChR or anti-MuSK antibody positive when specified criteria are met.

    Added ICD-10 diagnosis codes G70.00 and G70.01 to applicable codes.

    12 monthsinitial/reauthorization period
    J1823HCPCS code
    AQP4+NMOSD efficacy subgroup
    MG-ADL ≥5gMG baseline requirement
    87%IgG4-RD flare risk reduction
    52 wksIgG4-RD trial duration

    Coverage Criteria for Uplizna (inebilizumab-cdon)

    Initial Therapy — NMOSD

    Covered when ALL of the following are met for NMOSD:

    NMOSD Initial Criteria: Diagnosis of neuromyelitis optica spectrum disorder (NMOSD) by a neurologist with clinical history consistent with NMOSD (e.g., optic neuritis, acute myelitis, area postrema syndrome, acute brainstem syndrome, symptomatic diencephalic or cerebral syndromes); positive serologic test for anti‑aquaporin‑4 immunoglobulin G (AQP4‑IgG) antibodies; and alternative diagnoses (e.g., multiple sclerosis) ruled out.

    AQP4‑IgG seropositive patients derived benefit in pivotal trials

    Prior rituximab requirement: Either history of failure of rituximab therapy OR both: history of intolerance or contraindication to rituximab AND physician attestation that the same intolerance/severe adverse event would not be expected to occur with Uplizna.

    Step therapy requirement

    Prescribing and dosing: Uplizna is initiated and dosed according to the U.S. FDA labeled dosing for NMOSD and is prescribed by, or in consultation with, a neurologist.

    Initial authorization up to 12 months

    Concurrent therapy exclusions: Patient is not receiving Uplizna in combination with multiple sclerosis disease‑modifying therapies, complement inhibitors, anti‑IL‑6 therapy, or anti‑CD20 therapy for the same indication.

    Concurrent use is disallowed and may trigger denial

    Continuation Therapy — NMOSD

    For continuation of NMOSD therapy, ALL of the following are required:

    Clinical response and dosing: Documentation of positive clinical response to Uplizna and dosing per the U.S. FDA labeled dosing for NMOSD.

    Reauthorization will be for no more than 12 months

    Concurrent therapy exclusions: Patient is not receiving Uplizna in combination with multiple sclerosis disease‑modifying therapies, anti‑IL‑6 therapy, complement inhibitors, or anti‑CD20 therapy for the same indication.

    Initial Therapy — IgG4-RD

    Covered when ALL of the following are met for IgG4-RD:

    Diagnosis and classification: Diagnosis of immunoglobulin G4‑related disease (IgG4‑RD) with confirmation by a positive assessment using the ACR/EULAR classification criteria (organ involvement consistent with IgG4‑RD, negative exclusion criteria, and positive inclusion criteria).

    Specialist involvement recommended

    Prior therapy requirements: History of failure, contraindication, or intolerance to glucocorticoids AND either history of rituximab failure OR rituximab intolerance/contraindication with physician attestation that the same intolerance/severe adverse event would not be expected with Uplizna.

    Step therapy required before Uplizna

    Prescribing and dosing: Uplizna is initiated according to the U.S. FDA labeled dosing for IgG4‑RD and prescribed by, or in consultation with, a specialist with expertise in IgG4‑RD.

    Initial authorization up to 12 months

    Continuation Therapy — IgG4-RD

    For continuation of IgG4-RD therapy, ALL of the following are required:

    Clinical response and dosing: Documentation of positive clinical response to Uplizna and continued dosing per the U.S. FDA labeled dosing for IgG4‑RD; prescribed by, or in consultation with, an IgG4‑RD specialist.

    Reauthorization up to 12 months

    Concurrent therapy exclusions: Patient is not receiving Uplizna in combination with disease‑modifying therapy for IgG4‑RD (e.g., rituximab).

    Initial and Continuation Therapy — gMG

    Covered when ALL of the following are met for generalized myasthenia gravis (gMG):

    Diagnosis and antibody status: Diagnosis of generalized myasthenia gravis with positive serology for anti‑AChR or anti‑MuSK antibodies; patient has not previously failed a course of Uplizna.

    Provider must submit records confirming diagnosis and serology

    Disease severity: MGFA Clinical Classification of class II, III, or IV at initiation and MG‑ADL total score ≥ 5 at initiation.MG‑ADL ≥ 5

    Baseline severity required

    Prior therapy requirements by antibody: If anti‑AChR positive: either failure of at least two immunosuppressive agents over ≥12 months OR failure of at least one immunosuppressive therapy plus ≥4 courses of plasmapheresis/IVIG over ≥12 months; If anti‑MuSK positive: failure of at least one immunosuppressive agent over ≥12 months.

    Step therapy dependent on antibody status

    Initial Therapy — gMG (alternate location)

    Covered when ALL of the following are met

    Initial Therapy — gMG: Confirmed diagnosis of generalized myasthenia gravis; positive serologic test for anti‑AChR OR anti‑MuSK antibodies; MGFA Clinical Classification II, III, or IV at initiation; MG‑ADL total score ≥ 5 at initiation; patient has not failed prior Uplizna; Uplizna prescribed by or in consultation with a neurologist; dosing follows U.S. FDA label; Uplizna administered no sooner than two weeks after the first initial dose and every 6 months thereafter; initial authorization limited to ≤ 12 months.MG‑ADL ≥ 5

    Submission of supporting medical records required

    Prior therapy requirement by serostatus: If anti‑AChR positive: either failure of ≥2 immunosuppressive agents over ≥12 months OR failure of ≥1 immunosuppressive therapy plus ≥4 courses of plasmapheresis/IVIG over ≥12 months; If anti‑MuSK positive: failure of ≥1 immunosuppressive agent over ≥12 months.

    Step therapy documented in records

    Concurrent therapy exclusions: Patient is NOT receiving Uplizna in combination with complement inhibitors, FcRn blockers, or immune globulin for the same indication.

    Continuation Therapy — gMG

    Covered when ALL of the following are met

    Continuation Therapy — gMG: Patient previously treated with Uplizna; medical records demonstrate improvement and/or maintenance of at least a 2‑point improvement in MG‑ADL from pre‑treatment baseline; reduction in signs and symptoms of myasthenia gravis; maintenance, reduction, or discontinuation of baseline immunosuppressive therapy compared to pre‑Uplizna baseline (note: add‑on, dose escalation of IST, or additional rescue therapy while on Uplizna is considered treatment failure); patient is not receiving Uplizna sooner than 6 months from the start of the previous treatment cycle; Uplizna is not given in combination with complement inhibitors, FcRn blockers, or immune globulin for the same indication; reauthorization will be for no more than 12 months.≥ 2‑point improvement in MG‑ADL from pre‑treatment baseline

    Documentation of MG‑ADL and treatment history required

    IgG4-Related Disease (informational)

    Informational: FDA indication and trial evidence summarized

    IgG4‑RD FDA indication: Inebilizumab‑cdon (Uplizna) is FDA‑indicated for treatment of IgG4‑related disease in adults.

    Informational only

    Pivotal trial duration: Randomized, double‑blind, placebo‑controlled pivotal trial enrolled 135 adults with a 52‑week randomized controlled period.52 weeks

    Trial duration

    Efficacy outcomes: Inebilizumab significantly prolonged time to first treated and adjudicated IgG4‑RD flare versus placebo, reducing risk of treated AC‑determined flares by 87% (hazard ratio 0.13; p < 0.0001); 58.8% of Uplizna‑treated patients achieved steroid‑free, flare‑free complete remission at week 52 versus 22.4% for placebo.

    Key efficacy outcomes from trial

    Uplizna must not be used concurrently with other therapies that treat the same indication when those combinations create contraindications or overlap in mechanism of action. Examples listed in the policy include multiple sclerosis disease‑modifying therapies (e.g., dimethyl fumarate, fingolimod, ocrelizumab), complement inhibitors (e.g., eculizumab, ravulizumab), anti‑IL6 therapy (e.g., tocilizumab), and other agents noted in the policy. Concurrent administration with such agents for the same indication may trigger denial of coverage.

    For all indications, the policy requires dosing and scheduling consistent with the U.S. FDA label and specialty prescribing (prescribed by or in consultation with a neurologist or appropriate specialist). Where dosing intervals are specified (for example, no sooner than two weeks after the first initial dose and every 6 months thereafter for gMG), Uplizna must not be administered sooner than the permitted interval; administration sooner than the labeled interval is a basis for denial.

    Combination use of Uplizna with a complement inhibitor (for example, eculizumab, ravulizumab, zilucoplan), an FcRn blocker (for example, nipocalimab, rozanolixizumab, efgartigimod), or immune globulin preparations (e.g., Hizentra, Gammagard) for the same indication is explicitly disallowed by this policy and may result in denial of authorization.

    This prohibition applies to both initial and continuation therapy and is repeated in the gMG-specific criteria: patients must not be receiving Uplizna in combination with these classes of agents for treatment of the same indication.

    Inebilizumab demonstrated efficacy for neuromyelitis optica spectrum disorder (NMOSD) predominantly in the AQP4‑IgG seropositive subgroup. In the pivotal trial, anti‑AQP4 antibody positive patients had a large relative reduction in attack risk, whereas patients who were anti‑AQP4 antibody negative showed no evidence of benefit. Use of Uplizna for AQP4‑IgG seronegative NMOSD therefore is not supported by the trial evidence cited in this policy.

    For continuation (reauthorization) of Uplizna in generalized myasthenia gravis, the policy requires documentation that treatment is producing clinical benefit. Specifically, medical records must demonstrate at minimum an improvement and/or maintenance of at least a 2‑point improvement in MG‑ADL from pre‑treatment baseline, reduction in signs and symptoms of myasthenia gravis, and maintenance, reduction, or discontinuation of baseline immunosuppressive therapy. The policy states that add‑on therapy, dose escalation of baseline immunosuppressive therapy, or additional rescue therapy while on Uplizna is considered treatment failure and may render continuation not medically necessary.

    Similarly, for NMOSD and other indications the policy requires documentation of positive clinical response and adherence to labeled dosing for reauthorization; absence of clinical improvement or evidence of treatment failure per the policy criteria may lead to denial of continued coverage.

    Provider Actions, Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Uplizna (inebilizumab-cdon) for generalized myasthenia gravis (gMG). Initial and reauthorization approvals will be for no more than 12 months. Uplizna must be dosed according to the U.S. FDA labeled dosing and administered no sooner than two weeks after the first initial dose and every 6 months thereafter for subsequent infusions for gMG. For NMOSD and IgG4‑RD indications, initial and reauthorization will be for no more than 12 months and dosing must follow the U.S. FDA labeled regimens.

    • Initial and reauthorization: ≤ 12 months
    • gMG dosing interval: no sooner than 2 weeks after first initial dose, then every 6 months
    • NMOSD/IgG4‑RD: U.S. FDA labeled dosing
    Documentation Required

    gMG Prior Authorization Documentation

    For generalized myasthenia gravis (gMG), the following must be included with the prior authorization submission: positive serologic test results for anti‑AChR or anti‑MuSK antibodies; documentation of MGFA Clinical Classification (class II, III, or IV) at initiation; baseline Myasthenia Gravis Activities of Daily Living (MG‑ADL) total score ≥ 5; and prior therapy history consistent with serostatus-based requirements. Prescriptions must be by, or in consultation with, a neurologist.

    Coding and Clinical Thresholds

    Covered HCPCS CodesHCPCSCovered
    J1823Injection, inebilizumab-cdon, 1 mg.
    Diagnosis CodesICD-10
    D89.84IgG4-related disease
    G36.0Neuromyelitis optica [Devic]
    G70.00Myasthenia gravis without (acute) exacerbation
    G70.01Myasthenia gravis with (acute) exacerbation
    Applicable ICD-10 Diagnosis CodesICD-10
    G70.00Myasthenia gravis without (acute) exacerbation (added to policy)
    G70.01Myasthenia gravis with (acute) exacerbation (added to policy)
    inv-16: MG-ADL baseline
    MG-ADL baseline requirement>= 5 (MG-ADL total score at initiation)
    Clinical classification requiredMGFA Clinical Classification II, III, or IV at initiation
    Prescribing specialistPrescribed by or in consultation with a neurologist
    inv-17: MG-ADL total score
    MG-ADL total score threshold>= 5 at initiation of therapy
    Role in authorizationRequired for initial prior authorization for gMG

    Background and Clinical Evidence

    Inebilizumab‑cdon (Uplizna) is a CD19‑directed humanized afucosylated IgG1 monoclonal antibody that depletes CD19‑expressing B cells primarily via antibody‑dependent cellular cytolysis. The agent is FDA‑indicated for neuromyelitis optica spectrum disorder (NMOSD), immunoglobulin G4‑related disease (IgG4‑RD), and generalized myasthenia gravis (AChR‑ or MuSK‑antibody positive). Clinical trials demonstrated reduction in NMOSD attacks (notably in AQP4‑IgG seropositive patients) and a reduced risk of IgG4‑RD flares versus placebo.

    IgG4-Related Disease evidence

    Trial evidence details: Pivotal randomized trial (n=135) with 52‑week duration: time to first treated and adjudicated IgG4‑RD flare was significantly longer with inebilizumab; hazard ratio for treated flares 0.13 (87% reduction); 58.8% vs 22.4% steroid‑free, flare‑free complete remission at week 52 (inebilizumab vs placebo).

    Informational, high importance

    Definitions and Clinical Scales

    inv-28: Inebilizumab-cdon (Uplizna)
    Drug class and targetCD19-directed humanized afucosylated IgG1 monoclonal antibody
    Proposed mechanismBinds CD19 on pre-B and mature B lymphocytes leading to antibody-dependent cellular cytolysis
    Brand and genericUplizna (inebilizumab-cdon)
    inv-29: AQP4-IgG seropositive
    DefinitionAQP4-IgG seropositive: detectable anti–aquaporin-4 immunoglobulin G antibodies
    Clinical relevanceAQP4-IgG seropositive patients derived clear benefit from inebilizumab in NMOSD trials
    Evidence note
    Policy Summary
    Payersierra health and life
    PolicyUplizna (inebilizumab-cdon) — Clinical Coverage Criteria
    Policy CodePolicy 2026D0091J
    Change TypeModified coverage criteriaadded gMG indicationsremoved NMOSD relapse-count requirement
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with documented diagnosis, serology, MGFA class II–IV and MG-ADL ≥5 (for gMG) and required supporting medical records per policy.
    SourceLink
    On This Page
    Coverage Criteria for Uplizna (inebilizumab-cdon)Provider Actions, Authorization and Documentation RequirementsCoding and Clinical ThresholdsBackground and Clinical EvidenceDefinitions and Clinical Scales
    Concurrent therapy exclusions: Patient is not receiving Uplizna in combination with a disease‑modifying therapy for IgG4‑RD (e.g., rituximab).

    Concurrent use disallowed

    Dosing interval and prescribing: Uplizna given no sooner than two weeks after the first initial dose and every 6 months thereafter (subsequent infusions no sooner than 6 months from prior cycle), dosed per U.S. FDA label, and prescribed by, or in consultation with, a neurologist.

    Initial and reauthorization up to 12 months

    Concurrent therapy exclusions: Patient is not receiving Uplizna in combination with a complement inhibitor, an FcRn blocker, or immune globulin for the same indication.

    Concurrent use disallowed

    Concurrent use disallowed

    • Serologic test results: anti‑AChR or anti‑MuSK
    • MGFA class documentation: II, III, or IV at initiation
    • MG‑ADL score: baseline ≥ 5
    • Prescriber: neurologist (or consult)
    Documentation Required

    Required Supporting Medical Records

    Required clinical documentation for gMG prior authorization includes chart notes and laboratory reports showing diagnosis, serostatus, MGFA class, baseline and follow‑up MG‑ADL scores, and a detailed prior treatment history (agents, doses, dates, and response). Failure to submit complete records is grounds for denial or delay.

    • Chart notes confirming gMG diagnosis and that patient has not previously failed Uplizna
    • Serologic test results (anti‑AChR or anti‑MuSK)
    • MGFA classification and MG‑ADL baseline score (≥ 5)
    • Detailed prior therapy history: immunosuppressive agents, IVIG/PLEX courses, rituximab/glucocorticoid trials, dates, and outcomes
    Denial Risk

    Documentation Insufficiency — Denial Risk

    Denial risk increases when required documentation is missing or incomplete. Absent items that commonly trigger denials include: missing serology, no MGFA or MG‑ADL documentation, lack of prior therapy details (agents, duration, response), and no specialist-consult or neurologist attestation.

    • Missing serologic confirmation (anti‑AChR or anti‑MuSK)
    • No MGFA class or MG‑ADL baseline score
    • Incomplete prior therapy history (agents, duration, outcomes)
    • No documentation of specialist involvement
    Step Therapy

    Prior Therapy Requirements by Serostatus

    Prior therapy requirements differ by serostatus for gMG: anti‑AChR antibody positive patients must have either (a) history of failure of at least two immunosuppressive agents over ≥ 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate), or (b) history of failure of at least one immunosuppressive therapy plus ≥ 4 courses of plasmapheresis/plasma exchange and/or immune globulin over ≥ 12 months without symptom control. Anti‑MuSK antibody positive patients must have history of failure of at least one immunosuppressive agent over ≥ 12 months.

    • Anti‑AChR positive: ≥2 immunosuppressive agent failures over ≥12 months OR ≥1 immunosuppressive failure plus ≥4 courses of PLEX/IVIG over ≥12 months
    • Anti‑MuSK positive: ≥1 immunosuppressive agent failure over ≥12 months
    Step Therapy

    Prior Rituximab (or Glucocorticoid) Requirement

    For NMOSD and IgG4‑RD indications, a history of rituximab failure, intolerance, or contraindication must be documented prior to approval unless clinical criteria specify otherwise. If rituximab was not tolerated or is contraindicated, documentation must include provider attestation that the same intolerance or severe adverse event would not be expected with Uplizna.

    • NMOSD: history of rituximab failure OR intolerance/contraindication with attestation
    • IgG4‑RD: history of failure/contraindication/intolerance to glucocorticoids AND rituximab failure or documented intolerance/contraindication with attestation
    Billing Rule

    Concurrent Therapy and Dosing Interval Conflicts

    Uplizna must not be administered in combination with certain therapies for the same indication. For gMG, concurrent use with complement inhibitors (e.g., eculizumab, ravulizumab, zilucoplan), FcRn blockers (e.g., nipocalimab, rozanolixizumab, efgartigimod), or immune globulin (IVIG/SCIG) is prohibited. For NMOSD and IgG4‑RD, do not combine with disease‑modifying therapies for the same condition (e.g., rituximab, complement inhibitors, anti‑IL6 agents). Infusions given sooner than the allowable interval (e.g., <6 months for gMG maintenance or < labeled interval for other indications) may result in denial.

    • Prohibited concurrent therapies for gMG: complement inhibitors, FcRn blockers, immune globulin
    • Prohibited concurrent therapies for NMOSD/IgG4‑RD: disease‑modifying therapies for the same indication (e.g., rituximab, complement inhibitors, anti‑IL6)
    • Dosing interval conflict: administering Uplizna sooner than allowed (gMG: <6 months after prior cycle) can cause denial
    Documentation sourceSubmission of medical records confirming MG-ADL score is required
    inv-18: Continuation response threshold
    Continuation response threshold>= 2-point improvement in MG-ADL from pre-treatment baseline for reauthorization
    Additional continuation requirementsReduction in signs/symptoms of MG and maintenance/reduction/discontinuation of baseline IST compared to pre-Uplizna baseline
    Failure criteriaAdd-on or dose escalation of IST or additional rescue therapy while on Uplizna is considered treatment failure
    Anti-AQP4 antibody positive population showed ~77.3% relative reduction in NMOSD attacks (HR 0.227, p < 0.0001)
    inv-30: MG-ADL
    DefinitionMyasthenia Gravis Activities of Daily Living (MG-ADL) scale: patient-reported measure of symptom burden used as primary efficacy endpoint in gMG trials
    Role in trialsPrimary efficacy measure in the gMG trial; baseline thresholds required for enrollment and authorization
    Scoring useChange in MG-ADL used to assess clinical response (e.g., >=2-point improvement for continuation)
    inv-31: QMG score
    DefinitionQuantitative Myasthenia Gravis (QMG) score: 13-item scale (0–39) assessing muscle weakness; higher scores indicate greater impairment
    Use in trialsUsed as a secondary endpoint in the gMG trial (change from baseline in QMG at week 26)
    Scoring detailEach item rated 0–3; total possible score range 0 to 39